Having trouble accessing articles? Reset your cache.

Ruxolitinib: Postmarketing study data

Incyte said a 75 year old male with MF who was treated with ruxolitinib in the U.K. Phase II ROBUST trial was diagnosed with progressive multifocal leukoencephalopathy (PML). The company said it

Read the full 324 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE